Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

Executive Summary

A recent externally-led PFDD meeting on kidney xenotransplantation, rather than a specific disease, allowed for more tailored patient comments on the procedure, which could impact development plans going forward.

You may also be interested in...



FDA Drug Development Meetings May Be Better Model For Future CMS Patient-Listening Sessions

The ability for Medicare officials to follow-up on patient testimony could make the sessions more informative. They also don’t all have to be the same.

CMS Seeking Patient Comments On Negotiated Drugs Similar To US FDA’s PFDD Program

Statements on patient experience with the diseases treated by the drugs subject to price negotiation and how they impact their lives are requested; 10 meetings are planned for the fall.

Promise Of Pigs: Kidney Still Functioning A Month After Xenotransplantation

More than a month after surgeons at NYU Langone Health transplanted a pig kidney into a human being, the animal organ is still working. Surgeons say this is the longest a gene-edited pig kidney has functioned in a human body.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel